MIA-002: A randomised, vaginal microbicide trial assessing the safety of PRO 2000/5 gel (P) versus vehicle placebo in Uganda
| ISRCTN | ISRCTN02518250 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN02518250 |
| Secondary identifying numbers | MIA-002 Version 3 |
- Submission date
- 11/08/2005
- Registration date
- 15/09/2005
- Last edited
- 25/05/2010
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Mrs Julie Bakobaki
Scientific
Scientific
222 Euston Road
London
NW1 2DA
United Kingdom
| Phone | +44 (0)20 7670 4896 |
|---|---|
| jmb@ctu.mrc.ac.uk |
Study information
| Study design | Randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Not specified |
| Study type | Prevention |
| Scientific title | |
| Study acronym | MIA: Microbicides Initiative in Africa |
| Study objectives | That PRO 2000/5 (P) gel in 0.5% and 2% formulations are as safe and acceptable for women to use as a vehicle placebo gel |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | HIV-1 |
| Intervention | Two active study products (0.5% and 2% PRO 2000/5 Gel [P]) and a matched vehicle placebo (Placebo Gel [P]) inserted intra-vaginally twice a day for 28 days |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase II |
| Drug / device / biological / vaccine name(s) | PRO 2000/5 gel |
| Primary outcome measure | The primary end-points are local and systemic safety parameters, namely: 1. Deep (any size) or extensive superficial (greater than or equal to 4 times the size of the tip of a 5 x 10 mm cotton-tipped swab) genital epithelial disruption visible on naked eye examination or colposcopy 2. The appearance of a coagulation abnormality which is considered clinically relevant by the local investigator/Trial Management Group |
| Secondary outcome measures | The secondary end-points are: 1. Grade 3 clinical or laboratory adverse event confirmed on examination or repeat testing respectively, thought to be possibly or probably related to gel 2. Grade 3 unexpected vaginal bleeding as reported at interview or on a diary card or recorded on examination 3. Grade 1 unexpected vaginal bleeding not due to menses 4. Acceptability of gel as assessed by a semi-structured questionnaire 5. Alterations in vaginal flora assessed by Nugent score performed on Gram-stained slides |
| Overall study start date | 11/06/2003 |
| Completion date | 17/11/2004 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 45 Years |
| Sex | Female |
| Target number of participants | 180 |
| Key inclusion criteria | 1. Healthy* women aged between 18 and 45 2. Sexually active and likely to remain so for the duration of the study at a minimum rate of twice per week 3. Willing to undergo a genital infection screen 4. Willing to undergo a human immunodeficiency virus (HIV) test** 5. Willing to accept health education about condoms and to be supplied with condoms to be used at every episode of sexual intercourse during the study, and has used condoms before 6. Able to give informed consent 7. Either HIV negative or HIV positive in a monogamous sexual relationship with another person who is also HIV positive and who will give his signed consent to say he has been informed and understands about the trial * HIV-seropositive women will be eligible providing they fulfil all other criteria including exclusion 10, and have a primary partner who is also HIV-seropositive. Antiretroviral therapy is permitted provided it has been stable for 2 months prior to enrolment and is not expected to change during participation in the study ** Unnecessary if HIV-positivity documented in medical records at Nsambya Hospital |
| Key exclusion criteria | 1. Pregnant, wanting to become pregnant or within 6 weeks postpartum 2. Current genital tract epithelial ulceration/disruption 3. Untreated gonococcal, chlamydial, or trichomonal infection, syphilis or symptomatic bacterial vaginosis 4. Is HIV positive and in a sexual relationship with someone who is not HIV infected, who will not have an HIV test before the trial, and/or who will not sign a consent form for the trial 5. Abnormal (grade II) haematology, biochemistry 6. Cervical intraepithelial neoplasia (CIN) greater than or equal to CIN II within 3 months 7. Acute/subacute pelvic inflammatory disease 8. Clinical coagulation disorder 9. Latex allergy 10. Current, recent (within 2 weeks) or on-going ill health that necessitates drug treatment (other than prophylaxis) or attendance at hospital*** 11. Post-coital or intermenstrual bleeding in the past 3 months 12. (If post-natal) Persistent abnormal vaginal discharge 13. No reported use of condoms between screening and enrolment 14. Having participated in another microbicide trial in previous 30 days 15. Considered unlikely to be able to comply with protocol *** Except for HIV positive women from the HIV clinic, where the same exclusion applies without the phrase 'or ongoing'; women may enter the study following the initiation of appropriate treatment |
| Date of first enrolment | 11/06/2003 |
| Date of final enrolment | 17/11/2004 |
Locations
Countries of recruitment
- England
- Uganda
- United Kingdom
Study participating centre
222 Euston Road
London
NW1 2DA
United Kingdom
NW1 2DA
United Kingdom
Sponsor information
Imperial College London (UK)
University/education
University/education
St Mary's Campus
Clinical Trials Centre
Winston Churchill Wing
Winsland Mews
London
W2 1NY
England
United Kingdom
| Website | http://www.imperial.ac.uk |
|---|---|
"ROR" |
https://ror.org/041kmwe10 |
Funders
Funder type
Government
The project was funded by the European Commission
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/06/2010 | Yes | No |
